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Introduction
It is generally believed that once a cell has diﬀ  erentiated 
its fate is determined and stable. However, several experi-
ments have shown that a diﬀ  erentiated cell, in particular 
circumstances, can either proliferate to a terminal 
diﬀ  erentiated state or return to a less diﬀ  erentiated one, a 
process called dediﬀ   erentiation or ‘transdiﬀ  erentiation’ 
[1]. In fact, during dediﬀ   erentiation, cells undergo 
changes at diﬀ  erent levels: gene, protein, morphological 
and functional. Th   is turnover in the cell cycle is probably 
orchestrated by signaling pathways, the involvement of 
certain of which during cell dediﬀ  erentiation has been 
reported [2]. Among these pathways, Notch signaling 
plays a crucial role during cell fate assignment and 
diﬀ   erentiation/proliferation events. In vertebrates, 
muta  genesis and misexpression of Notch and its ligands 
have highlighted numerous roles of this pathway during 
embryogenesis and the early stages of development [3-5]. 
Notch signaling has been identiﬁ  ed in diﬀ  erent develop-
mental systems, especially neurogenesis [3,4] and hemato-
poeisis [5]. Th  ese studies show that Notch signaling, in 
combination with other cellular factors, inﬂ  uences 
diﬀ  erentiation, proliferation and apoptosis.
Th   e Notch signaling pathway is highly conserved, from 
worms to humans. It is considered an important pathway 
in the development and assignment of cell fates during 
embryogenesis and the early stages of development as 
well as in the maintenance of a stem cell population in 
many tissues throughout life [6,7]. Notch receptors are 
also responsible for the regulation of cell proliferation 
and diﬀ  erentiation, thus acting as on/oﬀ   switches that 
activate either proliferation or diﬀ  erentiation [6,7].
In this review, we focus on studies that investigated the 
expression pattern of Notch family members from 
immature to mature articular cartilage and the eventual 
involvement of the Notch pathway in the modulation of 
chondrocyte physiology in normal and damaged articular 
cartilage, particularly in ‘osteoarthritic conditions’. Recent 
studies revealed that Notch is expressed in murine 
chondrocytes during cartilage development and in 
chondrocytes from adult normal articular cartilage 
[8-10]. Th  erefore, understanding the underlying mecha-
nisms of Notch signaling during these phenotypical 
changes in chondrocytes occurring during osteoarthritis 
(OA) may eventually allow scientists to temporally and/
or spatially modulate this signaling pathway in order to 
help the cells to synthesize a new functional extracellular 
matrix and restore the functional properties of the 
articular cartilage.
Historical background of the Notch gene and 
components of the pathway
Notch was ﬁ  rst discovered in Drosophila melanogaster as 
a mutant gene. Th  e name ‘Notch’ derives from the 
mutations observed on the margins of the Drosophila
wings due to Notch mutations. Th  e  ﬁ  rst ‘Notch’ mutation 
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character was sex-linked, dominant in the female 
Drosophila, and lethal in the male. In 1917, Bridges [12] 
found a second mutation of this gene, and later several 
others were found [13]. ‘Notch’ refers either to the Notch 
genes, the Notch receptors or the Notch pathway, 
according to context.
Th  e Notch genes encode Notch receptors. Th  ese are 
300-kDa transmembrane proteins with a large extra-
cellular domain containing epidermal growth factor 
repeats essential for the ligand-receptor interaction and a 
cysteine rich region. Th   e intracellular domain consists of 
ankyrin repeats, a glutamine-rich domain and a PEST 
(proline, glutamate, serine, threonine) domain [14,15]. 
Th   e Notch genes diﬀ  er between species: Drosophila has 
one, and mammals four, expressing Notch receptors 1, 2, 
3 and 4.
Th   e Notch family also includes genes encoding ligands 
of the Notch receptors, Delta and Serrate, which are 
similarly conserved in both invertebrates and vertebrates. 
Drosophila has only one gene for Serrate and one for 
Delta, whereas in mammals ﬁ  ve genes encode the Notch 
ligands: Serrate homologues called Jagged1 and 2, and 
Delta homologues called Delta like 1, 3 and 4. Th  ese 
constitute the DSL (Delta/Serrate/Lag2) family (Figure 1).
Activation of the Notch pathway
Th  e  ﬁ  rst described Notch activation cascade consists of a 
series of cleavages leading to the release of the intra-
cellular domain of the receptor, which interacts in the 
nucleus with the transcription factor CSL (CBF 1 in 
humans, Suppressor of hairless in Drosophila, and LAG 
in Caenorhabditis elegans) to regulate the expression of 
the target genes [7]. However, recent studies suggest that 
the CSL-dependent [16,17] signaling pathway does not 
mediate all functions of Notch [18]. Th   us, Notch may act 
by two distinct processes: CSL-dependent signaling (the 
canonical pathway) [15] and CSL-independent signaling.
Canonical activation via CSL
Maturation and activation of the Notch receptor are 
conserved between species. Th  is process is initiated by 
cleavage in the trans-Golgi network by a furin convertase. 
Th  e resulting two fragments are re-associated and 
proceed to the cell surface as a transmembrane receptor, 
consisting of an extracellular domain and a Notch 
tethered membrane. Th  is complex interacts with a 
neighboring cell expressing the receptor’s ligand on its 
surface and the receptor becomes susceptible to a second 
cleavage by a metalloprotease from the ADAM (a desin-
tegrin and metalloprotease) family called TACE (tumor 
necrosis factor alpha converting enzyme). A third 
cleavage occurs within the transmembrane domain of the 
receptor and is carried out by γ-secretase, an enzyme 
that generally constitutively cleaves transmembrane 
proteins with short extracellular stubs. Th  is  ﬁ  nal cleavage 
liberates the intracellular domain of the Notch receptor, 
which translocates to the nucleus and interacts with its 
downstream transcription factor, CSL, and thereby 
activates transcription of its target genes [7,18-21] 
(Figure 2). To date, two major Notch primary target genes 
have been identiﬁ   ed, HES and HERP. Th  ese Notch 
eﬀ  ectors belong to the basic helix-loop-helix family and 
negatively regulate the expression of downstream target 
genes in diﬀ  erent tissues [22-24].
Non-canonical activation (CSL-independent)
Several studies have provided evidence for CSL-
independent Notch signaling [25,26]. Weinmaster and 
colleagues [25,26] showed that CSL-independent signal-
ing can prevent diﬀ  erentiation of the myogenic cell line 
C2C12; diﬀ  erentiation was still blocked in cells expres-
sing truncated forms of the Notch intracellular domain, 
which prevents the activation of the CSL-dependent 
promoter. Th   ese results were conﬁ  rmed by the co-culture 
of the C2C12 cell line with Jagged1-expressing cells. Th  ey 
concluded that Notch signaling can inhibit myogenesis 
independently of CSL. However, the ligand-induced 
activation of Notch may lead to signaling through both 
the CSL-independent and CSL-dependent pathways [26]. 
In 2008, Maillard and colleagues [27] inhibited the 
canonical Notch pathway in murine hematopoietic stem 
cells. Th  e abolishment of the CSL-dependent signal in 
these cells did not lead to any defect when allowed to 
compete with normal hematopoietic stem cells in vivo.
Figure 1. The main components of the Notch receptor and its 
ligands in mammals.
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to occur via Abl (Figure 2). Abl is a cytoplasmic tyrosine 
kinase that has been widely studied as a protein implicated 
in cell growth and fate guidance [28-33] and in the etiology 
of human cancer [34-36]. Interestingly, it has also been 
reported that mutations aﬀ  ecting Abl signaling result in 
small decreases in the eﬃ     ciency of Notch function, 
aﬀ  ecting cell identity [37]. On the contrary, deletion of the 
CSL-dependent pathway does not result in deleterious 
eﬀ   ects on central nervous system longitudinal axon 
development in Drosophila embryos [38].
Th  e Notch receptor may have diﬀ  erential abilities to 
trigger canonical and non-canonical signaling, which 
could eventually lead to reciprocal control of the two 
signaling pathways [39,40]. Th  e two Notch signaling 
pathways may interact in concert or in a coordinated 
manner to provide the necessary regulation of nuclear 
genes encoding cytoskeletal and cell adhesion proteins.
Role of Notch during cartilage development and 
adulthood
In vivo, cartilage is formed in mesenchymal cell conden-
sations during the early stages of development. Previous 
studies showed that Notch family members were 
expressed in early mesenchymal cell condensations of 
murine limb rudiments as well as in developing avian 
cartilage [9,41]. It has also been reported that Notch 
signaling is involved in the maturation of chondrocytes 
during chick limb development. Crowe and colleagues 
[42] investigated the expression pattern of Notch family 
members during chick limb development; they found 
that neither Notch 1 nor Serrate 1 or 2 were expressed, 
while Delta 1 and Notch 2 were detected. Th  ese  authors 
induced the misexpression of Delta 1 in the presumptive 
limb region of stage 13 to 16 chick embryos. Th  e  results 
showed that Delta 1 was speciﬁ   cally expressed in 
hypertrophic chon  dro  cytes during their formation and 
Figure 2. Canonical and non-canonical (Abl) Notch signaling pathways. A, co-activator; CSL, CBF, Su(H), Lag3; DSL, Delta, Serrate, Lag2; 
R, co-repressor; S1, S2, S3 and S4, Notch cleavage sites in the canonical signaling pathway; TACE, tumor necrosis factor alpha converting enzyme.
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Notch 2 receptor is ubiquitously expressed throughout 
the limb in all the chondrocytes. Moreover, Delta 1 
misexpression pre  vented prehypertrophic chondrocytes 
in the chick limb from diﬀ  erentiating into hypertrophic 
chondro  cytes, result  ing in a dramatic shortening of the 
cartilage ele  ments. In this context, the hypertrophic 
chondrocytes did eventually undergo programmed 
apoptosis and were replaced by osteoblasts and then 
osteocytes and ﬁ   nally formed the mature skeleton. In 
summary, according to these authors progression of 
chondrocytes from the prehypertrophic state to the 
hypertrophic state is negatively regulated by Notch/Delta 
signaling, which also controls the transition of 
chondrocytes to a terminally diﬀ  erentiated state [42-45]. 
In addition, Hayes and colleagues [46] showed that Notch 
receptor 1 was expressed in murine chondrocytes on the 
surface of articular cartilage before birth and that this 
expression becomes restricted to deeper layers after 
birth.
Th  ese data suggest that the presence of the Notch 
receptor is needed for cell diﬀ  erentiation and prolifera-
tion before birth in order to form the cartilage elements. 
During the late stages of development and after birth the 
expression of the Notch receptor would instead allow the 
terminal diﬀ  erentiation and maturation of chondrocytes 
in the deeper layers of cartilage, thus promoting osteo-
chondral ossiﬁ   cation. One of the most relevant 
hypotheses is that Notch may act as an on/oﬀ   switch, 
either enabling maturation of the articular cartilage by 
promoting cell proliferation or acting as a terminal 
diﬀ  erentiation potential leading to bone formation (and 
bone elongation after birth).
In order to elucidate the role of Jagged, Oldershaw and 
colleagues [47] transduced human mesenchymal stem 
cells (hMSCs) with adenoviral Jagged1. Th   e results of the 
chondrogenic cell aggregate culture showed a total 
inhibition of chondrogenesis versus normal chondro-
genesis in vector control transduced hMSCs. It has also 
been shown that long-term Notch/Jagged signaling main-
tains the progenitor cell state [47,48]. Taken together, the 
results of these studies suggest that Notch/Jagged 
signaling promotes the maintenance of the progenitor 
phenotype and even suppresses cell diﬀ  erentiation.
It was also reported that the activation of Notch signal-
ing during development is a matter of timing. Grogan 
and colleagues [49] showed that the over-expression of 
the Notch intracellular domain in hMSC pellet culture 
induced a reduction in type II collagen mRNA levels, 
suggesting an inhibition of chondrogenesis. However, 
inhibition of Notch activity by using a γ-secretase 
inhibitor (the enzyme responsible for Notch activation) 
at diﬀ  erent stages of chondrogenesis showed that Notch 
activation and signaling is only necessary during early 
chondrogenic diﬀ   er  entiation. To further elucidate the 
mechanisms of the Notch repressive response during 
chondrogenesis, these authors over-expressed the Notch 
eﬀ  ectors HES-1/HEY-1 in hMSCs. Th   e results showed an 
alteration in type II collagen and aggrecan expression, 
thus conﬁ  rming the essential role played by Notch during 
chondrocyte diﬀ   erentiation. In 2010, Oldershaw and 
colleagues [50] showed that inhibiting Notch activation 
for 14 days in hMSC aggregate culture was only as 
eﬀ  ective as blocking the pathway during the ﬁ  rst 5 days, 
conﬁ  rming previous reports by Grogan and colleagues 
[49]. Th  ese results suggest that once Notch has been 
activated during chondrogenesis, further Notch signaling 
is not needed [49,50].
Recent studies showed that Notch family members are 
still expressed in articular cartilage subpopulations even 
after birth [51,52]. In this context, the continuous 
development of articular carti  lage, as well as the presence 
of a chondroprogenitor subpopulation and its fate, might 
be regulated by the Notch pathway. Since chondrocyte 
diﬀ  erentiation and maturation continue into early stages 
of development, recent and current studies are more 
interested in the expression of Notch in post-birth and 
mature articular cartilage. Indeed, Dowthwaite and 
colleagues [51] showed that Notch receptor was 
expressed on the surface of articular cartilage of a 7-day-
old calf by a progenitor cell population; this matches 
previous results in developing mouse articular cartilage 
[8]. Th  ese cells were shown to have increased colony 
forming eﬃ     ciency compared with chondrocytes not 
expressing Notch receptor, suggesting a primordial role 
for the Notch receptor in controlling the clonality of 
surface zone chondrocytes [51]. In fact, in both species 
the Notch receptor is present in the chondrocytes of the 
surface zone of the articular cartilage. Consistent with 
these results, Grogan and colleagues showed that over 
70% of chondrocytes on the surface zone of adult human 
articular cartilage express Notch1 receptor [49,53]. 
Additionally, Karlsson and colleagues [10] cultured 
human articular chondrocytes for one passage with and 
without treatment by a Notch signaling inhibitor; the 
results showed that blocking Notch activation decreases 
chondrocyte proliferation compared with controls.
Although these data support the idea that Notch 
signaling is mainly involved in maintaining clonality and 
proliferation rather than diﬀ  erentiation, it has not been 
excluded that this pathway may also promote chondro-
cyte terminal diﬀ  erentiation [42]. Th  us, the precise role 
of the Notch receptor in promoting proliferation or 
diﬀ  erentiation after birth remains unclear.
Notch and damaged articular cartilage
In normal conditions, the chondrocyte is responsible for 
the synthesis, maintenance and turnover of the 
Sassi et al. Arthritis Research & Therapy 2011, 13:208 
http://arthritis-research.com/content/13/2/208
Page 4 of 8extra cellular  matrix of articular cartilage. Th  is matrix is 
primarily composed of type II collagen and aggrecans [54]. 
In normal articular cartilage, low turnover of extra  cellular 
matrix components is maintained by a balance between 
anabolic and catabolic factors. In fact, metallo  proteinases, 
especially matrix metalloproteinase (MMP)13, are pro-
duced by chondrocytes in order to ensure the continuous 
renewal of collagen ﬁ  brils. Th  is production is regulated 
by the synthesis of tissue inhibitors of MMPs, commonly 
called TIMPs. During OA, degradation of the extra-
cellular matrix exceeds its synthesis, resulting in a net 
decrease in the amount of cartilage matrix and even the 
erosion of joint surfaces [55]. Additionally, chondrocytes 
undergo phenotypic modiﬁ   cations, including the 
acquisition of a ﬁ  broblast-like morphology, loss of the 
ability to express collagen II, and increased expression of 
fetal ﬁ  brillar collagen type I, usually known as chondro-
cyte dediﬀ  erentiation. Th   ese phenotypical modiﬁ    ca tions 
promote matrix degradation and unsuccessful cartilage 
repair [56,57]. Kouri and Lavalle [1] established a classiﬁ  -
cation scheme for chondrocytes present in OA cartilage 
based on their ultrastructural characteristics. Th  ey 
identiﬁ  ed three types, ranging from normal chondrocytes 
on non-ﬁ  brillated regions to secretory chondrocytes with 
irregular shape, and apoptotic (chondroptotic) chondro-
cytes in the deeper ﬁ   brillated regions. Th  us, they 
suggested that, following cartilage injury, the chondro-
cyte is activated and the types of molecules it secretes 
changes, called the transdiﬀ   er en tiation  process.  Th  is 
mechanism is launched in an attempt to repair cartilage, 
and the failure of this repair results in apoptosis of 
chondrocytes [1].
In this context, the recently reported expression of 
Notch family members in adult and even OA cartilage 
raised the issue of the involvement of this pathway in the 
physiopathology of OA and especially in the changes that 
chondrocytes undergo during this process [51,52]. 
Experimental animal models of OA that have been 
developed, such as rabbit, rat and dog, have rather 
focused on the anatomopathology of the disease [58-63]. 
Th  us, scientists have been interested in studying the 
relationship between morphology and chondrocyte 
behavior  in vitro using monolayer cultures to induce 
dediﬀ  erentiation, although it has been realized that the 
monolayer expansion of chondrocytes can alter the 
diﬀ  er  entiated phenotype [64]. Th  is was conﬁ  rmed in a 
murine model of chondrocyte culture in which cells 
switched from expressing type II collagen to type I and 
III collagen starting from day 4 to 8 of culture. Th  e  switch 
in collagen synthesis occurred simultaneously with a loss 
of the chondrocyte matrix capsule and the emergence of 
a ﬁ  broblast-like morphology [64].
It has been reported that passaged articular chondro-
cytes in a murine model undergo morphological and 
structural changes similar to the changes observed in OA 
chondrocytes, notably a decrease in the expression of 
type II collagen and an increase in the expression of type 
I collagen [65]. Some studies have highlighted an eventual 
involvement of Notch signaling during the dediﬀ  erentia-
tion of murine chondrocytes: Blaise and colleagues [66] 
and our group [67] studied the expression pattern of 
Notch family members in passaged immature murine 
articular chondrocytes that had been treated or not with 
a γ-secretase inhibitor. Th   e results show that the 
untreated chondrocytes had decreased expression of type 
II collagen during the passages but increased MMP13 
expression. However, cells treated with the inhibitor 
during the passages showed a less pronounced decrease 
in collagen II synthesis and a decrease in MMP13 expres-
sion [66]. Th  ese authors also showed that transfecting 
chondrocytes with the active form of the Notch receptor 
resulted in reduction of MMP13 expression. Moreover, 
our group showed that the inhibition of this pathway not 
only slowed the dediﬀ   erentiation process, but also 
inhibited collagen I expression and even led to collagen II 
re-expression, suggesting eventual chondrocyte re-
diﬀ  erentiation [67].
Since Notch signaling is involved not only in diﬀ  eren-
tiation but also in proliferation and apoptosis in 
developing and mature articular cartilage, recent studies 
have focused on the involvement of this pathway in joint 
pathology. Several studies were interested in the 
interaction between Notch signaling and cartilage sub-
populations [68,69]. In 2004, Alsalameh and colleagues 
[70] showed that normal human articular cartilage may 
contain a mesenchymal progenitor population, and in 
2006, Hiraoka and colleagues [52] linked the expression 
of the Notch receptor 1 with the presence of a mesen-
chymal progenitor population.
Consistent with these results, Karlsson and colleagues 
[71] and Grogan and colleagues [72] showed that the 
frequency of cells expressing Notch1 is higher in ﬁ  bril-
lated OA cartilage compared to healthy cartilage. In the 
same context, Archer and colleagues [73], in a recent 
study, isolated and characterized the previously described 
chondroprogenitor population from human adult articu-
lar cartilage. Th   ey described this subpopulation as retain-
ing a ‘stem cell-like phenotype’, and the activation of these 
cells probably depends on the physiological and patho-
logical parameters surrounding articular chondrocytes.
Th   ere is a debate in the literature concerning the origin 
of this subpopulation. Functional studies were interested 
in the multilineage potential of these cells. Barbero and 
colleagues [74] used monolayer expansion of adult human 
chondrocytes to show that these cells exhibited diﬀ  er-
entiation plasticity toward chondrocytic, osteoblastic and 
adipocytic lineages, suggesting that monolayer expansion 
may induce selection for progenitor cells. Th   is was later 
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selected chontrocytes from OA patients. Diﬀ  erentiation 
assays performed by Grogan and colleagues [72] also 
showed that a subpopulation of chondrocytes represent-
ing 0.1% of the cartilage cells displayed a higher 
multilineage potential than the rest of the chondrocytes.
Other studies have studied chondrocyte surface 
markers in order to elucidate the origin of the chondro-
progenitor population. Diaz-Romero and colleagues [75] 
analyzed changes in surface immunologic markers during 
chondrocyte monolayer expansion and showed that the 
cell surface marker proﬁ  le of dediﬀ  erentiated chondro-
cytes has similarities to that previously described for 
hMSCs. For a better understanding of the origin of 
dediﬀ   erentiating chondrocytes, these authors [76] iso-
lated and cultured human articular chondrocytes and 
hMSCs and compared their cell surface immunomarker 
proﬁ  les.  Th  e results showed that the cartilage cells 
exhibiting changes in these markers are actually multi-
potent dediﬀ   erentiating chondrocytes rather than a 
subpopulation of hMSCs proliferating during monolayer 
expansion. Th  ese results are in accordance with the 
hypothesis reported by De La Fuente and colleagues [77], 
who showed that dediﬀ   erentiated human articular 
chondrocytes should be considered as a multipotent 
primitive population.
In summary, whether they are dediﬀ  erentiated 
multipotent chondrocytes or a preexisting hMSC popu-
lation, these data conﬁ  rm the eventual involvement of 
this subpopulation in pathologic cartilage remodeling. 
Hiraoka and colleagues [52] showed by immunohisto-
chemistry that this chondroprogenitor population in 
adult human articular cartilage expresses Notch recep-
tors and their ligands Jagged and Delta, which may 
increase the clonality of these cells. Th   is expression was 
increased in OA cartilage, which the authors suggested 
might be due to the large number of chondrocytes in the 
clusters observed during OA, which are thought to 
represent cells that hyperproliferated in response to 
tissue injury [52]. Th  ese results suggest that articular 
cartilage cells (mature chondrocytes and/or mesen  chy-
mal progenitor cells) expressing Notch family members 
may be activated during OA in order to achieve intrinsic 
cartilage repair.
Conclusion
OA is a multifactorial disease and the degradation of the 
articular cartilage is a complex process involving several 
actors, including signaling pathways like the Notch 
pathway. Further work is required to understand the 
complexity of Notch signaling during cartilage pathology 
and chondrocyte dediﬀ   erentiation, which is likely to 
become a new research focus because of its importance 
in the stem cell ﬁ  eld, regenerative medicine and aging 
biology. Understanding the underlying mechanisms of 
chondrocyte dediﬀ   erentiation is necessary to develop 
new therapeutic approaches for a better outcome for 
patients suﬀ  ering from joint diseases.
Abbreviations
hMSC, human mesenchymal stem cell; MMP, matrix metalloproteinase; OA, 
osteoarthritis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
N Sassi: conception and design, collection and assembly of data, drafting of 
the article, critical revision of the article. L Laadhar: collection and assembly 
of data, critical revision of the article for important intellectual content, fi  nal 
approval of the article. M Driss: conception and design, critical revision of the 
article for important intellectual content, fi  nal approval of the article. M Kallel-
Sellami: conception and design, critical revision of the article for important 
intellectual content, fi  nal approval of the article. S Sellami: conception and 
design, critical revision of the article for important intellectual content, fi  nal 
approval of the article. S Makni: conception and design, critical revision of the 
article for important intellectual content, fi  nal approval of the article.
Author details
1Osteoarthritis-osteoporosis Research Laboratory, Rheumatology Department, 
LaRabta Hospital, 1007 Tunis, Tunisia. 2Immunology Department, LaRabta 
Hospital, 1007 Tunis, Tunisia. 3Anatomo-pathology Department, Salah Azaiez 
Health Institute, 1007 Tunis, Tunisia.
Published: 18 March 2011
References
1.  Kouri JB, Lavalle C: Do chondrocytes undergo activation and 
transdiff  erentiation during the pathogenesis of osteoarthritis? A review of 
the ultrastructural and immunohistochemical evidence. Histol Histopathol 
2006, 21:793-802.
2.  Cai SA, Fu X, Sheng Z: Dediff  erentiation: a new approach in stem cell 
research. Bioscience 2007, 57:655-662.
3.  Greenberg DA, Jin K: Turning neurogenesis up a Notch. Nat Med 2006, 
12:884-885.
4.  Yoon K, Gaiano N: Notch signaling in the mammalian central nervous 
system: insights from mouse mutants. Nat Neurosci 2005, 8:709-715.
5.  Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin 
RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden 
DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 
2003, 425:841-846.
6.  Tsakonas S A, Matsuno K, Fortini M: Notch signaling. Science 1995, 
268:225-232.
7.  Tsakonas SA, Rand MD, Lake RJ: Notch signaling: cell fate control and signal 
integration in development. Science 1999, 284:770-776.
8.  Hayes AJ, Dowthwaite GP, Webster SV, Archer CW: The distribution of Notch 
receptors and their ligands during articular cartilage development. J Anat 
2003, 202:495-502.
9.  Watanabe N, Tezuka Y, Matsuno K, Miyatani S, Morimura N, Yasuda M, Fujimaki 
R, Kuroda K, Hiraki Y, Hozumi N, Tezuka K: Suppression of diff  erentiation and 
proliferation of early chondrogenic cells by Notch. J Bone Miner Metab 
2003, 21:344-352.
10.  Karlsson C, Jonsson M, Asp J: Notch and HES5 are regulated during human 
cartilage diff  erentiation. Cell Tissue Res 2007, 327:539-551.
11. Dexter  JS:  The analysis of a case of continuous variation in Drosophila by a 
study of its linkage relations. Am Nat 1914, 48:712-758.
12. Bridges  CB:  Defi  ciency. Genetics 1917, 2:445-465.
13. Morgan  LV:  Non-criss-cross inheritance in Drosophila melanogaster. Biol Bull 
1922, 42:267-274.
14. Brou  C:  intracellular traffi   cking of Notch receptors and ligands. Exp Cell Res 
2009, 315:1549-1555.
15.  Talora C, Campese AF, Bellavia D, Felli MP, Vacca A, Gulino A, Screpenti I: 
Notch signaling and diseases: an evolutionary journey from a simple 
beginning to complex outcomes. Biochem Biophys Acta 2008, 1782:489-497.
Sassi et al. Arthritis Research & Therapy 2011, 13:208 
http://arthritis-research.com/content/13/2/208
Page 6 of 816.  Egan S E, Pierre B, Leow C: Notch receptors, partners and regulators: from 
conserved domains to powerful functions. Curr Top Microbiol Immunol 
1998, 228:273-324.
17.  Kao HY, Ordentlich P, Koyano Nakagawa N, Tang Z, Downes M, Kintner CR, 
Evans RM, Kadesch T: A histone desacetylase corepr  essor complex 
regulates the Notch signal transduction pathway. Genes Dev 1998, 
12:2269-2277.
18.  Arias AM, Zecchini V, Brennan K: CSL-independant Notch signaling: 
a checkpoint in cell fate decisions during development? Curr Opin Gene 
Dev 2002, 12:524-533.
19. Fortini  M:  Notch and presenilin: a proteolytic mechanism emerges. Curr 
Opin Cell Biol 2001, 13:627-634.
20. Schweisguth  F:  Regulation of Notch signaling activity. Curr Biol 2004, 
14:129-138.
21.  Fiùza UM, Arias AM: Cell and molecular biology of Notch. J Endocrinol 2007, 
194:459-474.
22.  Ohsako S, Hyer J, Panganiban G, Oliver I, Caudy M: Hairy function as a DNA-
binding helix-loop-helix repressor of Drosophila sensory organ formation. 
Genes Dev 1994, 8:2743-2755.
23.  Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R: 
Hes1 and Hes5 as notch eff  ectors in mammalian neuronal diff  erentiation. 
EMBO J 1999, 18:2196-21207.
24.  Iso T, Kedes L, Hamamori Y: HES and HERP families: multiple eff  ectors of the 
Notch signaling pathway. J Cell Physiol 2003, 194:237-255.
25.  Shawber C, Nofziger D, Hsieh JD, Lindsell C, Bögler O, Hayward D, Weinmaster 
G: Notch signaling inhibits muscle cell diff  erentiation through a CBF1- 
independent pathway. Development 1996, 122:3765-3773.
26.  Donna Nofziger D, Alison Miyamoto A, Karen M, LyonsKM, Weinmaster G: 
Notch signaling imposes two distinct blocks in the diff  erentiation of 
C2C12 myoblasts. Development 1999, 126:1689-1702.
27.  Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, 
Bhandoola A, Radtke F, Pear WS: Canonical Notch signaling is dispensable 
for the maintenance of adult hematopoietic stem cells. Stem Cell 2008, 
2:356-366.
28.  Baum B, Perrimon N: Spatial control of the actin cytoskeleton in Drosophila 
epithelial cells. Nat Cell Biol 2001, 3:883-890.
29.  Bear JE, Loureiro JJ, Libova I, Fassler R, Wehland J, Gertler FB: Negative 
regulation of fi  broblast motility by Ena/VASP proteins. Cell 2000, 
101:717-728.
30.  Gertler FB, Bennett RL, Clark MJ, Hoff  mann FM: Drosophila Abl tyrosine 
kinase in embryonic CNS axons: A role in axonogenesis is revealed 
through dosage-sensitive interactions with disabled. Cell 1989, 58:103-113.
31.  Grevengoed EE, Loureiro JJ, Jesse TL, Peifer M: Abelson kinase regulates 
epithelial morphogenesis in Drosophila. J Cell Biol 2001, 155:1185-1198.
32. Luo  L:  Trio quartet in D. melanogaster. Neuron 2000, 26:1-2.
33.  Wills Z, Bateman J, Korey CA, Comer A, Van Vactor D: The tyrosine kinase Abl 
and its substrate enabled collaborate with the receptor phosphatase Dlar 
to control motor axon guidance. Neuron 1999, 22:301-312.
34.  Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, 
Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Effi   cacy and safety of a 
specifi  c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid 
leukemia. N Engl J Med 2001, 344:1031-1037.
35.  Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD, 
Croce CM: A new fused transcript in Philadelphia chromosome positive 
acute lymphocytic leukemia. Nature 1987, 330:386-388.
36. Goff   SP, Gilboa E, Witte ON, Baltimore D: Structure of the Abelson murine 
leukemia virus genome and the homologous cellular gene: Studies with 
cloned viral DNA. Cell 1980, 22:777-785.
37. Giniger  E:  A role for Abl in Notch signaling. Neuron 1998, 20:667-681.
38.  Le Gall M, De Matter C, Giniger E: Molecular separation of two signaling 
pathways for the receptor Notch. Dev Biol 2008, 313:556-567.
39.  Espinosa L, Ingles-Esteve J, Robert-Moreno A, Bigas A: IkappaBalpha and p65 
regulate the cytoplasmic shuttling of nuclear corepressor: crosstalk 
between Notch and NFkappaB pathways. Mol Biol Cell 2003, 14:491-502.
40.  Vacca A Felli M.P, Palermo R, Di Mario G, Calce A, Di Giovine M, Frati L, Gulino 
A, Screpanti I: Notch3 and pre-TCR interaction unveils distinct NF-kappaB 
pathways in T-cell development and leukemia. EMBO J 2006, 25:1000-1008.
41.  Williams R, Nelson L, Dowthwaite GP, Evans DJ, Archer CW: Notch receptor 
and Notch ligands expression in developing avian cartilage. J Anat 2009, 
215:159-169.
42.  Crowe R, Zikherman J, Niswander L: Delta 1 negatively regulates the 
transition from prehypertrophic chondrocytes to hypertrophic 
chondrocytes. Development 1999, 126:987-998.
43.  Bolos V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and 
cancer. Endocr Rev 2007, 28:339-369.
44.  Henson FM, Bowe EA, Daves ME: Promotion of the intrinsic damage-repair 
response in articular cartilage by fi  broblast growth factor. Osteoarth Cartil 
2005, 13:537-544.
45.  Hardingham TE, Oldershaw R, Tew RS: Cartilage, sox9 and Notch signals in 
chondrogenesis. J Anat 2006, 209:469-480.
46.  Hayes AJ, MacPherson S, Morrisson H, Dowthwaite GP, Archer CW: The 
development of articular cartilage evidence of an appositional growth 
mechanism. Anat Embryol 2001, 203:469-479.
47.  Oldershaw R, Murdoch A, Brennan K: The putative role of the Notch ligand, 
jagged1, in the mediation of the early events of human mesenchymal 
stem cell chondrogenesis. Int J Exp Pathol 2005, 86:47-48.
48.  Kageyama R, Ohtsuka T, Hatakeyama J, Ohsawa R: Roles of bHLH genes in 
neural stem cell diff  erentiation. Exp Cell Res 2005, 306:343-348.
49.  Grogan SP, Tsaiwei Olee T, Hiraoka K, , Lotz MK: Notch signaling proteins 
Hes-1 and Hey-1 bind N-box domains in the Col2a1 enhancer site to 
repress chondrogenesis. Arthritis Rheum 2008, 58:2754-2763.
50.  Oldershaw R, Hardingham TE: Notch signaling during chondrogenesis of 
human bone marrow stem cells. Bone 2010, 46:286-293.
51.  Dowthwaite G, Bishop J, Redman S, Khan IM, Rooney P, Evans DJR, Haughton 
L, Bayram Z, Boyer S, Thomson B, Wolfe MS, Archer CW: The surface of 
articular cartilage contains a progenitor cell population. J Cell Sci 2004, 
117:889-897.
52.  Ustunel I, Ozenci AM, Sahin Z, Ozbey O, Acar N, Tanriover G, Celik-Ozenci C, 
Demir R: The immunohistochemical localization of Notch receptors and 
ligands in human articular cartilage, chondroprogenitor culture and 
ultrustructural characterestics of these progenitor cells. Acta Histochem 
2008, 110:397-407.
53.  Grogan SP, Miyaki S, Asahara H, D’Lima D, Lotz MK: Mesenchymal progenitor 
cell markers in human articular cartilage: normal distribution and changes 
in osteoarthritis. Arthritis Res Ther 2009, 11:R85.
54.  Laadhar L, Zitouni M, Kallel-Sellami M, Mahjoub M, Sellami S, Makni S: 
Physiopathology of osteoarthritis: from normal cartilage to osteoarthritic 
cartilage: risk factors and infl  ammatory mechanisms. Rev Med Int 2007, 
28:531- 536.
55.  Nagase H, Kashiwagi M: Aggrecanases and cartilage matrix degradation. 
Arthritis Res 2003, 5:94-103.
56.  Poole A R, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, Sakai T, Wahl C, 
El-Madawy S, Webb G, Tchetina E, Wu W: Type II collagen degradation and 
its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 2002, 
61:78-81.
57.  Van Beuningen HM, stoop R, Buma P, Takahashi N, Van Der Kraan PM, Van Den 
Berg WB: Phenotypic diff  erences in murine chondrocyte cell lines from 
mature articular cartilage. Osteoarth Cartil 2002, 10:977-986.
58.  Eyre DR, McDevitt CA, Billigham MEG, Muir H: Biosynthesis of collagen and 
other matrix proteins by articular cartilage in experimental osteoarthritis. 
Biochem J 1998, 188:823-837.
59.  Burton-Wuster N, Hui-Chou CS, Greisen HA, Lust G: Reduced deposition of in 
the degenerated articular cartilage of dogs with degenerative joint 
disease. Biochem Biophys Acta 1982, 718:74-84.
60.  Miller DR, Lust G: Accumulation of procollagen in the degenerative 
articular cartilage of dogs with osteoarthritis. Biochem Biophys Acta 1979, 
583:218-231.
61.  Abbud Lozoya K, Kouri JB: A novel rat osteoarthritis model to assess 
apoptosis and matrix degradation. Pathol Res Pract 2000, 196:729-745.
62.  Kouri Flores JB, Abbud Lozoya K, Morales RL: Kinetics of the ultrastructural 
changes in apoptotic chondrocytes from an osteoarthritic rat model: 
a window of comparison to the cellular mechanisms of apoptosis in 
human chondrocytes. Ultrastructur Pathol 2002, 26:33-40.
63.  Matyas JR, Huang D, Chung M, Adams ME: Regional quantifi  cation of 
cartilage type II collagen and aggrecan messenger RNA in joints with early 
experimental osteoarthritis. Arthritis Rheum 2002, 46:1536-1543.
64.  Grundmann K, Zimmermann B, Barrach HJ, Merker HJ: Behaviour of 
epiphyseal mouse chondrocyte populations in monolayer culture: 
Morphological and immunohistochemical studies. Virchows Arch A Pathol 
Anat Histol 1980, 389:167-187
65.  Salvat C, Pigenet A, Humbert L, Berembaum F, Thirion S: Immature murine 
articular chondrocytes in primary culture: a new tool for investigating 
Sassi et al. Arthritis Research & Therapy 2011, 13:208 
http://arthritis-research.com/content/13/2/208
Page 7 of 8cartilage. Osteoarth Cartil 2005, 13:243-249.
66.  Blaise R, Mahjoub M, Salvat C, Barbe U, Brou C, Corvol MT, Savouret JF, 
Rannou F, Berenbaum F, Bausero P: Involvement of the Notch pathway in 
the regulation of matrix metalloproteinase 13 and the de-diff  erentiation 
of articular chondrocytes in murine cartilage. Arthritis Rheum 2009, 
60:428-439.
67.  Sassi N, Laadhar L, Mahjoub M, Kallel-Sellami M, Zitouni M, Makni S, Sellami S: 
Expression of Notch family members in cultured murine articular 
chondrocytes. Biotech Histochem 2009, 84:313-320.
68.  Svanvik T, Barreto Henriksson H, Karlsson C, Hagman M, Lindahl A, Brisby H: 
Human disk cells from degenerated disks and mesenchymal stem cells in 
co-culture result in increased matrix production. Cells Tissues Organs 2010, 
191:2-11.
69.  Dong Y, Jesse AM, Kohn A, Gunnell LM, Honjo T, Zuscik MJ, O’Keefe RJ, Hilton 
MJ: RBPjk-dependent Notch signaling regulates mesenchymal progenitor 
cell proliferation and diff  erentiation during skeletal development. 
Development 2010, 137:1461-1471.
70.  Alsalameh S, Amin R, Gemba T, Lotz M: Identifi  cation of mesenchymal 
progenitor cells in normal and osteoarthritic human articular cartilage. 
Arthritis Rheum 2004, 50:1522-1532.
71.  Hiraoka K, Grogan S, Olee T, Lotz M: Mesenchymal progenitor cells in adult 
human articular cartilage. Biorheology 2006, 43:447-454.
72.  Karlsson C, Brantsing C, Egell S, Lindahl A: Notch1, Jagged1, and HES5 are 
abundantly expressed in osteoarthritis. Cells Tissues Organs 2008, 
188:287-298.
73.  Williams R, Ilyas M, Khan IK, Kirsty Richardson K, Larissa Nelson L, McCarthy H, 
Analbelsi T, Singhrao SK, Dowthwaite GP, Jones RE, Baird DM, Lewis H, Roberts 
S, Shaw HM, Dudhia J, Fairclough J, Briggs T, Archer CW: Identifi  cation and 
clonal characterisation of a progenitor cell sub-population in normal 
human articular cartilage. PLoS ONE 2010, 5:e13246.
74.  Barbero A, Ploegert S, Herherer M, Martin I: Plasticity of clonal populations 
of dediff  erentiated adult human articular chondrocytes. Arthritis Rheum 
2003, 48:1315-1325.
75.  Diaz-Romero J, Gaillard JP, Grogan SP, Nesic D, Trub T, Mainil-Varlet P: 
Immunophenotypic analysis of human articular chondrocytes: changes in 
surface markers associated with cell expansion in monolayer culture. J Cell 
Physiol 2005, 202:731-742.
76.  Diaz-Romero J, Nesic D, Grogan SP, Heini P, Mainil-Varlet P: 
Immunophenotypic changes of human articular chondrocytes during 
monolayer culture refl  ect bona fi  de dediff  erentiation rather than 
amplifi  cation of progenitor cells. J Cell Physiol 2008, 214:75-83.
77.  De la Fuente R, Abad JL, Castro JG, Miguel GF, Petriz J, Rubio D, Abejon CV, 
Guillen P, Gonzalez MA, Bernada A: Dediff  erentiated adult articular 
chondrocytes: a population of human multipotent primitive cells. Exp Cell 
Res 2004, 297:313-328.
doi:10.1186/ar3255
Cite this article as: Sassi N, et al.: The role of the Notch pathway in healthy 
and osteoarthritic articular cartilage: from experimental models to ex vivo 
studies. Arthritis Research & Therapy 2011, 13:208.
Sassi et al. Arthritis Research & Therapy 2011, 13:208 
http://arthritis-research.com/content/13/2/208
Page 8 of 8